Rocket Lab's Earnings Report: Beyond the Headlines – Surprises, Controversies, and What's Next
Rocket Lab (RKLB) just released its Q4 earnings, and while the headline numbers show a revenue beat, there's a lot more to the story. But here's where it gets controversial: some key metrics, like EPS, paint a more nuanced picture, and the Neutron delay raises questions about execution. Let's dive into the details and uncover what the market might be missing.
Live Coverage: Unraveling the Story in Real-Time
We're bringing you live updates as new information emerges. Stay tuned for the latest developments, key insights, and market reactions as they unfold.
Four Surprises That Could Move the Needle
While Rocket Lab's Q4 revenue beat expectations, four key surprises emerged that the headline numbers don't fully capture, potentially explaining the muted stock reaction:
EPS: Miss or Match? The reported GAAP EPS of -$0.09 appears to miss the consensus estimate of -$0.01. However, Alpha Vantage data suggests an estimate of -$0.09, making it a match. This discrepancy itself is surprising and highlights the importance of considering multiple data sources.
Neutron's Concrete Delay: The Neutron launch has been pushed to Q4 2026 due to a Stage 1 tank test failure. This replaces a vague 'H1 2026' target with a specific, trackable delay, introducing execution risk.
Margin Compression Ahead: Q1 2026 GAAP gross margin guidance of 34%-36% marks a step back from Q4's ~38%. This reversal after a record margin run was unexpected and warrants close attention.
Prediction Market Volatility: Polymarket odds on an earnings beat fluctuated dramatically, dropping to 58% pre-release and surging to 99.9% post-release. This suggests late uncertainty not reflected in analyst estimates, raising questions about market sentiment.
Digging Deeper: Context is Key
The EPS Context Is Complicated: The apparent EPS miss is more nuanced than it seems. The consensus figure of -$0.01 appears to be an outlier, with Alpha Vantage data pointing to -$0.09, making the result in line with expectations. This highlights the importance of considering multiple data points and avoiding oversimplification.
Margin Compression: A Temporary Setback? The guided margin compression in Q1 2026 raises concerns. While attributed to mix and investment timing, investors will be watching closely to see if this is a temporary blip or a sign of a broader trend.
Neutron's Delay: Execution Risk or Learning Curve? The Neutron delay due to a tank test failure is a setback. While ground testing is designed to identify issues, the six-month-plus slip raises questions about the program's timeline and potential impact on future projects.
Q4 Scorecard: A Mixed Bag
Our Q4 scorecard paints a mixed picture:
- Revenue: A solid A, with $179.65M beating estimates and FY25 revenue reaching $601.80M.
- Earnings: A C, with GAAP EPS of -$0.09 missing the consensus estimate.
- Guidance: A strong A, with Q1 FY26 guidance of $185M-$200M implying ~57% YoY growth.
- Margins: A B, with GAAP gross margin guided down to 34%-36% in Q1.
- Cash Flow: A B, with over $1 billion in liquidity providing runway for Neutron development.
- Management Confidence: An A, with CEO Peter Beck projecting strong momentum despite the Neutron delay.
Overall Grade: B+
Rocket Lab delivered a revenue beat and record backlog, but the EPS miss and Neutron delay temper the enthusiasm. The $185M-$200M Q1 guidance is the key takeaway, with margin compression a critical area to watch.
Looking Ahead: 5 Key Questions
- Neutron's Timeline: Will the Q4 2026 target hold, or will further delays emerge? How will management address execution concerns?
- Margin Expansion: Can Rocket Lab sustain its long-term margin expansion goals despite near-term compression?
- Electron's Momentum: Will the 50th mission milestone translate into sustained contract wins and increased launch cadence?
- Defense Contracts: Will Rocket Lab secure significant contracts like SDA Tranche 3, solidifying its position in the defense sector?
- Path to Profitability: When will Rocket Lab achieve profitability, and how will it manage cash burn during Neutron development?
The Bottom Line: A Crucial Inflection Point
Rocket Lab stands at a critical juncture. While the Electron business is strong and the space systems segment is growing, Neutron's success is pivotal. With shares trading below analyst targets, the market is demanding execution. This quarter's results and management's narrative will be crucial in determining whether Rocket Lab can live up to its potential.
What's your take? Do you think Rocket Lab can overcome the Neutron delay and margin compression concerns? Share your thoughts in the comments below!
